Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Diagnosis (Berl) ; 9(2): 157-165, 2021 10 22.
Article in English | MEDLINE | ID: mdl-34674417

ABSTRACT

OBJECTIVES: We provide a systematic literature review on tissue miRNAs in patients with RCC to evaluate and summarize their usefulness as prognostic markers. We undertook a systematic search for articles in English using the PubMed-Medline database from January 2010 to December 2020. Studies were identified and selected according to the PRISMA criteria and the PICO methodology. The population consisted of RCC patients undergoing nephrectomy and the main outcome of interest was recurrence-free survival (RFS). Only studies providing hazard ratios (HRs) from multivariate or univariate analyzes with corresponding 95% confidence intervals (CI) and/or area under the curve (AUC) were considered. CONTENT: All nine included studies (1,541 patients) analyzed the relationship between tissue miRNA expression levels (up or downregulated) and RFS. Some of these found that the methylation status of miR-9-1, miR-9-3 and miR-124 was associated with a high risk of relapse. Moreover, miR-200b overexpression was associated with OS. MiR-210 overexpression indicated a shorter OS than those who were miR-210 negative. Finally, patients with high miR-125b expression had shorter cancer-specific survival (CSS) than those with low expression; similarly, patients with low miR-126 expression also had shorter CSS time. SUMMARY AND OUTLOOK: Several studies tested the usefulness of specific miRNAs to predict RCC recurrence. Some of them showed a fair accuracy and strong relationship between specific miRNA over or under-expression and survival outcomes. However, results from these studies are preliminary and miRNAs use in routine clinical practice is still far to come.


Subject(s)
Carcinoma, Renal Cell , Kidney Neoplasms , MicroRNAs , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Carcinoma, Renal Cell/genetics , Carcinoma, Renal Cell/surgery , Humans , Kidney Neoplasms/genetics , Kidney Neoplasms/surgery , MicroRNAs/genetics , MicroRNAs/metabolism , Nephrectomy , Prognosis
2.
Arch Ital Urol Androl ; 93(1): 64-67, 2021 Mar 19.
Article in English | MEDLINE | ID: mdl-33754611

ABSTRACT

INTRODUCTION: Testicular cancers represent about 5% of all urological malignancies and 1-1.5% of all male neoplasms. Most of the testicular cancers are localized (68%) at diagnosis. Bulky masses in the scrotum are rare. We present a rare case of bulky testicular cancer with retroperitoneal spread through the inguinal canal. CASE REPORT: A 44-year-old man came to the emergency department referring weakness and the presence of a scrotal mass. At physical examination, a voluminous mass was found, with necrotic phenomena within the scrotum. Abdomen was tense and sore. Abdominal CT scan revealed a bulky testicular mass spreading to the retroperitoneal space through the inguinal canal with node enlargement. Patient underwent orchiectomy with excision of infiltrated scrotum skin. Histologic diagnosis confirmed a typical form seminoma. The patient was then treated with a cisplatin-based chemotherapy, with a partial response. The patient recently relapsed and he is being treated with a new line of chemotherapy and subsequent surgery with or without radiotherapy. CONCLUSIONS: We described a rare presentation of testicular cancer. This case highlights the importance of a multidisciplinary approach to rare testis tumour presentation and early diagnosis for testicular cancers.


Subject(s)
Inguinal Canal/pathology , Retroperitoneal Neoplasms/pathology , Seminoma/pathology , Testicular Neoplasms/pathology , Adult , Humans , Male , Neoplasm Invasiveness , Retroperitoneal Neoplasms/complications , Retroperitoneal Neoplasms/therapy , Seminoma/complications , Seminoma/therapy , Testicular Neoplasms/complications , Testicular Neoplasms/therapy , Ulcer/complications
SELECTION OF CITATIONS
SEARCH DETAIL
...